Meeting
2022 ASCO Annual Meeting
A phase 1b study to evaluate safety, tolerability, pharmacokinetics, and efficacy of SER-155 in adults undergoing hematopoietic stem cell transplantation to reduce the risk of infection and graft versus host disease (NCT04995653).
Authors
Doris M. Ponce
Memorial Sloan Kettering Cancer Center, New York, NY
Doris M. Ponce , Mary-Jane Lombardo , Christopher B. Ford , Jonathan U. Peled , Marcel R. M. Van Den Brink , Bindu Tejura
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Allogenic Stem Cell Transplantation
Clinical Trial Registration Number
NCT04995653
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS7074)
DOI
10.1200/JCO.2022.40.16_suppl.TPS7074
Abstract #
TPS7074
Poster Bd #
299b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 1b study to evaluate the efficacy, safety, and pharmacokinetics of an investigational microbiome therapeutic, SER-155, in adults undergoing hematopoietic stem cell transplantation.
First Author: Doris M. Ponce
Poster
2022 ASCO Annual Meeting
Efficacy and safety of SER-109, an investigational microbiome therapeutic for recurrent clostridioides difficile infection: Data from ECOSPOR III, a phase 3 randomized trial.
First Author: Alla Paskovaty
Poster
2024 ASCO Annual Meeting
Biomarkers in a phase 1b study of investigational microbiome therapeutic SER-155 in adults undergoing allogeneic hematopoietic cell transplantation (allo-HCT).
First Author: Doris M. Ponce
Poster
2023 ASCO Annual Meeting
Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of GEC255, a novel KRASG12C inhibitor, in advanced solid tumors.
First Author: Yan Zhang